Kimberly-Clark’s $48.7 Billion Acquisition Raises Questions on Corporate Concentration and Consumer Choice

In a sweeping move that reshapes the landscape of America’s consumer health products, Kimberly-Clark announced its acquisition of Tylenol maker Kenvue in a deal valued at approximately $48.7 billion. This mega-merger combines stalwarts like Tylenol, Band-Aid, Kleenex, Cottonelle, and Huggies into a single corporate giant poised to generate around $32 billion in annual revenue.Is Bigger Always Better for American Consumers?While the promise of streamlined operations and cost savings—projected at nearly $1.9 billion within three years—may sound appealing to investors and executives, Americans should ask: What does this mean for choice and competition? The merger creates one of the largest purveyors...